Company intelligence / Profile preview
SynerGene Therapeutics, Inc.
Potomac, Maryland, United Statesbloomberg.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has multiple clinical trials including a Phase 2 study of SGT-53 plus gemcitabine/nab-paclitaxel for metastatic pancreatic cancer, and an early Phase 1 study of SGT-53 with irradiation and chemotherapy in children with recurrent CNS malignancies. Their technology delivers therapeutic genes specifically to targeted disease sites while avoiding healthy cells.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Gene therapyNanocomplex delivery systemsPlasmid DNAsiRNA/miRNAAS ODNSmall moleculesChemotherapy drugsImaging agents
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on SynerGene Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SynerGene Therapeutics, Inc..